Enfuvirtide

CLINICAL USE

Treatment of HIV-1 in combination with other antiretroviral agents

DOSE IN NORMAL RENAL FUNCTION

90 mg twice daily

PHARMACOKINETICS

Molecular weight :4491.9

%Protein binding :92

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :4.4–6.6 litres

half-life – normal/ESRD (hrs) :3.2–4.4/Probably unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

35–50 Dose as in normal renal function10–35 Dose as in normal renal function1

<10 : Dose as in normal renal function1

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :13% dialysed.1 Dose as in GFR <10 mL/min

HDF/high flux :Unlikely to be dialysed. Dose as in GFR <10 mL/min

CAV/VVHD :Unlikely to be dialysed. Dose as in GFR=10–35 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

1.1 mL water for injection

Route

Rate of Administration

–

Comments

Do not shake vial or turn it upside down as this causes foamingThe powder may take up to 45 minutes to dissolveUse within 24 hours if kept in refrigerator. Allow to reach room temperature before injecting

OTHER INFORMATION

Renal calculi have been reported with enfuvirtide therapyC max and AUC are increased in CKD 5 patients

Tags: post-by-auto-php